Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VOX · 2 trials · 1 indication
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study treatment.
| Arm | Type | Description |
|---|---|---|
| VOX+SOF/VEL 6 wk, TN, without cirrhosis | EXPERIMENTAL | VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis) |
| VOX+SOF/VEL 8 wk, TN, without cirrhosis | EXPERIMENTAL | VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis) |
| VOX+SOF/VEL 6 wk, TN, with cirrhosis | EXPERIMENTAL | VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis) |
| VOX+SOF/VEL 8 wk, TN, with cirrhosis | EXPERIMENTAL | VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis) |
| VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis | EXPERIMENTAL | VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis) |
| VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis | EXPERIMENTAL | VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis) |
| VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis | EXPERIMENTAL | VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis) |
| VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis | EXPERIMENTAL | GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis) |
| VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis | EXPERIMENTAL | GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis) |
| VOX+SOF/VEL 12 wk (GS-US-338-1121) | EXPERIMENTAL | VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study) |
| GS-9857+SOF/VEL 6 wk, TN, with cirrhosis | EXPERIMENTAL | GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis) |
| VOX+SOF/VEL 8 wk,TE, without cirrhosis | EXPERIMENTAL | GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis) |
| VOX+SOF/VEL 12 wk, TE, without cirrhosis | EXPERIMENTAL | VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis) |
| GS-9857+SOF/VEL 8 wk, TE, with cirrhosis | EXPERIMENTAL | GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis) |
| VOX+SOF/VEL 12 wk, TE, with cirrhosis | EXPERIMENTAL | VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis) |
| Name | Type | Description |
|---|---|---|
| VOX | DRUG | 100 mg tablet(s) administered orally once daily with food |
| SOF/VEL | DRUG | 400/100 mg FDC tablet administered orally once daily with food |
| RBV | DRUG | Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) |
Key Inclusion Criteria: * Individuals with chronic HCV infection * HCV RNA ≥10\^4 IU/mL at screening * HCV genotype 1 * Cirrhosis determination; a liver biopsy may be required * Screening laboratory values within defined thresholds * Use of two contraception methods if female of childbearing potent...
VOX is an investigational small molecule being studied for the treatment of Hepatitis C Virus Infection. It is in Phase 2 clinical development and is being evaluated in combination with sofosbuvir and velpatasvir as a fixed dose combination in adults with chronic HCV infection.
VOX is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker GILD. The company is conducting clinical trials of VOX in combination with other antiviral agents for the treatment of Hepatitis C Virus Infection.
VOX is in Phase 2 clinical development. Two Phase 2 trials of VOX have been completed, both evaluating the drug in combination with sofosbuvir and velpatasvir for the treatment of chronic Hepatitis C Virus Infection in adults.
VOX has been studied in two completed Phase 2 clinical trials. NCT02378935 evaluated VOX plus sofosbuvir and velpatasvir in adults with chronic genotype 1 HCV infection, enrolling 205 participants. NCT02378961 evaluated the same combination in adults with chronic non-genotype 1 HCV infection, enrolling 128 participants.
VOX is the abbreviated name for voxilaprevir, an investigational small molecule being developed by Gilead Sciences for the treatment of Hepatitis C Virus Infection. It is being studied in combination with sofosbuvir and velpatasvir as a fixed dose combination therapy.